RxDoctor Payments Data

Rachel Zonca, DO

Family Medicine · Santa Maria, CANPI 1619357092

Payments from drug & device makers

$8,564in general payments, 2019–2025

Across 515 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • Pfizer$876
  • Novo Nordisk$820
  • Lilly USA, LLC$668
  • Boehringer Ingelheim$517
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,552100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,564 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$254,291
Medicare patients
521
Services billed
2,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$129,443
FarxigaDapagliflozin Propanediol60$64,549
EliquisApixaban38$50,089
MounjaroTirzepatide35$46,925
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$38,137
JardianceEmpagliflozin25$35,424
JanuviaSitagliptin Phosphate21$26,866
Repatha SureclickEvolocumab21$25,680
OxycontinOxycodone Hcl13$25,418
LinzessLinaclotide18$19,249
WegovySemaglutide14$18,253
MyrbetriqMirabegron18$14,490
Praluent PenAlirocumab17$13,166
XareltoRivaroxaban14$11,829
TrintellixVortioxetine Hydrobromide15$10,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$820$147,695124 claims
AstraZenecaFarxiga$239$64,54960 claims
PfizerEliquis$876$50,08938 claims
Lilly USA, LLCMounjaro$668$46,92535 claims
GSKTrelegy Ellipta$416$38,13738 claims
MerckJanuvia, Belsomra$138$37,22941 claims
Boehringer IngelheimJardiance$517$35,42425 claims
AbbVieLinzess, Synthroid$1,275$21,15146 claims
Astellas Pharma US IncMyrbetriq$67$14,49018 claims
Johnson & JohnsonXarelto$111$11,82914 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$85$10,76515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →